Literature DB >> 20978199

BRAF inactivation drives aneuploidy by deregulating CRAF.

Tamihiro Kamata1, Jahan Hussain, Susan Giblett, Robert Hayward, Richard Marais, Catrin Pritchard.   

Abstract

Aspartate-594 is the third most common BRAF residue mutated in human cancer. Mutants of this residue are kinase inactive, and the mechanism(s) by which they contribute to cancer has remained perplexing. Using a conditional knock-in mouse model, we show that the (D594A)Braf mutant does not drive tumor development per se but is able to induce aneuploidy in murine splenocytes and mouse embryonic fibroblasts and contributes to immortalization through the propagation of aneuploid cells. (D594A)Braf lacks kinase activity but induces the related gene product Craf as well as the mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK pathway. Here, we show that the aneuploid phenotype is dependent on Craf. Treatment with the MEK inhibitor U0126 did not attenuate the emergence of aneuploidy but prevented the growth of aneuploid cells. These results provide a previously unidentified link between Craf and chromosomal stability, with important implications for our understanding of the development of cancers with driver mutations that hyperactivate Craf. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20978199      PMCID: PMC2975377          DOI: 10.1158/0008-5472.CAN-10-0603

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

Review 1.  RAS oncogenes: the first 30 years.

Authors:  Marcos Malumbres; Mariano Barbacid
Journal:  Nat Rev Cancer       Date:  2003-06       Impact factor: 60.716

2.  Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

Authors:  Paul T C Wan; Mathew J Garnett; S Mark Roe; Sharlene Lee; Dan Niculescu-Duvaz; Valerie M Good; C Michael Jones; Christopher J Marshall; Caroline J Springer; David Barford; Richard Marais
Journal:  Cell       Date:  2004-03-19       Impact factor: 41.582

Review 3.  Guilty as charged: B-RAF is a human oncogene.

Authors:  Mathew J Garnett; Richard Marais
Journal:  Cancer Cell       Date:  2004-10       Impact factor: 31.743

4.  MEK kinase activity is not necessary for Raf-1 function.

Authors:  M Hüser; J Luckett; A Chiloeches; K Mercer; M Iwobi; S Giblett; X M Sun; J Brown; R Marais; C Pritchard
Journal:  EMBO J       Date:  2001-04-17       Impact factor: 11.598

5.  Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse.

Authors:  Shigemi Hayashi; Andrew P McMahon
Journal:  Dev Biol       Date:  2002-04-15       Impact factor: 3.582

6.  Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.

Authors:  Sonja J Heidorn; Carla Milagre; Steven Whittaker; Arnaud Nourry; Ion Niculescu-Duvas; Nathalie Dhomen; Jahan Hussain; Jorge S Reis-Filho; Caroline J Springer; Catrin Pritchard; Richard Marais
Journal:  Cell       Date:  2010-01-22       Impact factor: 41.582

Review 7.  Raf proteins and cancer: B-Raf is identified as a mutational target.

Authors:  Kathryn E Mercer; Catrin A Pritchard
Journal:  Biochim Biophys Acta       Date:  2003-06-05

8.  BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice.

Authors:  Darren J Baker; Karthik B Jeganathan; J Douglas Cameron; Michael Thompson; Subhash Juneja; Alena Kopecka; Rajiv Kumar; Robert B Jenkins; Piet C de Groen; Patrick Roche; Jan M van Deursen
Journal:  Nat Genet       Date:  2004-06-20       Impact factor: 38.330

9.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

View more
  27 in total

1.  Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.

Authors:  Banibrata Sen; Shaohua Peng; Ximing Tang; Heidi S Erickson; Hector Galindo; Tuhina Mazumdar; David J Stewart; Ignacio Wistuba; Faye M Johnson
Journal:  Sci Transl Med       Date:  2012-05-30       Impact factor: 17.956

2.  Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation.

Authors:  Chad M Beneker; Magdalini Rovoli; George Kontopidis; Michael Röring; Simeon Galda; Sandra Braun; Tilman Brummer; Campbell McInnes
Journal:  J Med Chem       Date:  2019-04-12       Impact factor: 7.446

3.  BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS.

Authors:  Liping Zhang; Rajesh R Singh; Keyur P Patel; Francesco Stingo; Mark Routbort; M James You; Roberto N Miranda; Guillermo Garcia-Manero; Hagop M Kantarjian; L Jeffrey Medeiros; Rajyalakshmi Luthra; Joseph D Khoury
Journal:  Am J Hematol       Date:  2014-02-10       Impact factor: 10.047

4.  An Update on the Biology of RAS/RAF Mutations in Colorectal Cancer.

Authors:  Mandayam O Nandan; Vincent W Yang
Journal:  Curr Colorectal Cancer Rep       Date:  2011-06-01

5.  The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.

Authors:  Catherine Andreadi; Lai-Kay Cheung; Susan Giblett; Bipin Patel; Hong Jin; Kathryn Mercer; Tamihiro Kamata; Pearl Lee; Alexander Williams; Martin McMahon; Richard Marais; Catrin Pritchard
Journal:  Genes Dev       Date:  2012-08-14       Impact factor: 11.361

6.  RAF-isotype switching: from B to C through PDE.

Authors:  Eric Lau; Ze'ev Ronai
Journal:  Nat Struct Mol Biol       Date:  2011-05       Impact factor: 15.369

7.  Activation loop phosphorylation regulates B-Raf in vivo and transformation by B-Raf mutants.

Authors:  Martin Köhler; Michael Röring; Björn Schorch; Katharina Heilmann; Natalie Stickel; Gina J Fiala; Lisa C Schmitt; Sandra Braun; Sophia Ehrenfeld; Franziska M Uhl; Thorsten Kaltenbacher; Florian Weinberg; Sebastian Herzog; Robert Zeiser; Wolfgang W Schamel; Hassan Jumaa; Tilman Brummer
Journal:  EMBO J       Date:  2015-12-10       Impact factor: 11.598

8.  A Braf kinase-inactive mutant induces lung adenocarcinoma.

Authors:  Patricia Nieto; Chiara Ambrogio; Laura Esteban-Burgos; Gonzalo Gómez-López; María Teresa Blasco; Zhan Yao; Richard Marais; Neal Rosen; Roberto Chiarle; David G Pisano; Mariano Barbacid; David Santamaría
Journal:  Nature       Date:  2017-08-02       Impact factor: 49.962

9.  KRASG12D expression in lung-resident myeloid cells promotes pulmonary LCH-like neoplasm sensitive to statin treatment.

Authors:  Tamihiro Kamata; Susan Giblett; Catrin Pritchard
Journal:  Blood       Date:  2017-05-26       Impact factor: 22.113

10.  Mechanisms of aneuploidy induction by RAS and RAF oncogenes.

Authors:  Tamihiro Kamata; Catrin Pritchard
Journal:  Am J Cancer Res       Date:  2011-03-29       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.